Allarity Therapeutics Q1 net loss $2.7M, cash $27.7M; stenoparib shows durable benefit

Allarity Therapeutics, Inc.

Net loss narrowed to $2.7M in Q1 2025 from $3.8M in Q1 2024; R&D expenses $1.4M, G&A $1.6M.
Cash and restricted cash $27.7M at March 31, 2025, up from $20.9M at December 31, 2024.
Two ovarian cancer patients on stenoparib >19 months; new Phase 2 protocol for platinum-resistant disease begins H1 2025.
VA-funded Phase 2 trial of stenoparib + temozolomide in SCLC to begin enrollment Q2-Q3 2025.
Authorized $5M share repurchase program; ~2M shares bought; SEC settlement and class action lawsuit resolved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.